Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Alongi

Showing results (281-290 of 305) with videos related to

Pageof 31
Sort By:
Critical Reviews in Oncology/Hematology|January 20, 2019
Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicityStefano Arcangeli, Barbara Alicia Jereczek-Fossa, Filippo Alongi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 20, 2024
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E<sup>2</sup>-RADIatE OligoCare studySebastian M Christ, Filippo Alongi, Umberto Ricardi, et al.
Critical Reviews in Oncology/Hematology|September 5, 2024
The emerging role of Artificial Intelligence in proton therapy: A reviewLars Johannes Isaksson, Federico Mastroleo, Maria Giulia Vincini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2026
Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohortInes Joye, Umberto Ricardi, Marta Scorsetti, et al.
Therapeutic Advances in Urology|March 14, 2025
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est)Fabio Matrone, Luca Urso, Rossano Girometti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 24, 2021
An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiationFinbar Slevin, Katharine Aitken, Filippo Alongi, et al.
The Lancet. Oncology|February 19, 2026
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort studyTimo F W Soeterik, Marcin Miszczyk, Max Peters, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2025
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)Giulio Francolini, Niccolò Bertini, Vanessa Di Cataldo, et al.
Pageof 31

Showing results (281-290 of 305) with videos related to

Sort By:
Pageof 31
Critical Reviews in Oncology/Hematology|January 20, 2019
Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicityStefano Arcangeli, Barbara Alicia Jereczek-Fossa, Filippo Alongi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 20, 2024
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E<sup>2</sup>-RADIatE OligoCare studySebastian M Christ, Filippo Alongi, Umberto Ricardi, et al.
Critical Reviews in Oncology/Hematology|September 5, 2024
The emerging role of Artificial Intelligence in proton therapy: A reviewLars Johannes Isaksson, Federico Mastroleo, Maria Giulia Vincini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2026
Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohortInes Joye, Umberto Ricardi, Marta Scorsetti, et al.
Therapeutic Advances in Urology|March 14, 2025
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est)Fabio Matrone, Luca Urso, Rossano Girometti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 24, 2021
An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiationFinbar Slevin, Katharine Aitken, Filippo Alongi, et al.
The Lancet. Oncology|February 19, 2026
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort studyTimo F W Soeterik, Marcin Miszczyk, Max Peters, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2025
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)Giulio Francolini, Niccolò Bertini, Vanessa Di Cataldo, et al.
Pageof 31